Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Beijing Sun-Novo Pharmaceutical Research Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 4/6
Beijing Sun-Novo Pharmaceutical Research has a total shareholder equity of CN¥1.1B and total debt of CN¥421.0M, which brings its debt-to-equity ratio to 39%. Its total assets and total liabilities are CN¥1.9B and CN¥822.4M respectively. Beijing Sun-Novo Pharmaceutical Research's EBIT is CN¥215.6M making its interest coverage ratio 34.1. It has cash and short-term investments of CN¥534.4M.
Anahtar bilgiler
39.0%
Borç/özkaynak oranı
CN¥421.03m
Borç
| Faiz karşılama oranı | 34.1x |
| Nakit | CN¥534.42m |
| Eşitlik | CN¥1.08b |
| Toplam yükümlülükler | CN¥822.36m |
| Toplam varlıklar | CN¥1.90b |
Son finansal sağlık güncellemeleri
Recent updates
Concerns Surrounding Beijing Sun-Novo Pharmaceutical Research's (SHSE:688621) Performance
Sep 05
Market Still Lacking Some Conviction On Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHSE:688621)
Jul 31We Think Beijing Sun-Novo Pharmaceutical Research (SHSE:688621) Can Stay On Top Of Its Debt
May 29Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 688621's short term assets (CN¥1.4B) exceed its short term liabilities (CN¥710.2M).
Uzun Vadeli Yükümlülükler: 688621's short term assets (CN¥1.4B) exceed its long term liabilities (CN¥112.1M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 688621 şirketinin toplam borcundan daha fazla nakdi var.
Borcun Azaltılması: 688621's debt to equity ratio has increased from 8.2% to 39% over the past 5 years.
Borç Kapsamı: 688621's debt is not well covered by operating cash flow (16.6%).
Faiz Kapsamı: 688621's interest payments on its debt are well covered by EBIT (34.1x coverage).